drugset / Trial / NCT03370874

Clinical Study to Evaluate Efficacy and Safety of ALLO-ASC-DFU in Patients With Diabetic Foot Ulcers.

NCT03370874

Phase 3 Completed 150 enrolled Anterogen Co., Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a phase III double-blind study to evaluate the efficacy and safety of ALLO-ASC-DFU in patients with Diabetic Foot Ulcer, compared to placebo therapy.

Timeline

Start
2018-06-27
Primary completion
2019-12-09
Completion
2020-02-20

Drugs

EvaluationDrugModalityDoseRoute
Subject mesenchymal stem cells Cell therapy

Indications